A study presented at the CHEST Annual Meeting found that treatment with immune checkpoint inhibitors increased the risk of venous thromboembolism in adults with metastatic lung cancer. Specifically, those who received anti-PD-1 therapy had a higher risk for pulmonary embolism compared to those who received anti-PD-L1 agents. The study, which reviewed data from the TriNetX Research Network database, showed a higher incidence of thromboembolic events among ICI recipients compared to non-recipients. Clinicians treating patients with metastatic lung cancer with ICIs should be aware of the heightened risk of thromboembolism and monitor for symptoms.
Source link
Immune checkpoint inhibitors for advanced lung cancer linked to higher blood clot risk
